Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASBRON vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Relief of symptoms of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema,Symptomatic relief of productive cough associated with respiratory conditions
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
AEROLONE is not a recognized drug; no standard dosing available.
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Theophylline is primarily metabolized by cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Guaifenesin is metabolized via oxidation and glucuronidation.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
50-60% bound to albumin and alpha-1-acid glycoprotein
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: 40-60%; rectal: 50-70%; inhalation: 10-30%
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR 30-59 m L/min: reduce dose by 25-50%; GFR <30 m L/min: reduce dose by 50% and monitor serum theophylline levels.
No data; not applicable.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B or C: reduce dose by 75% and monitor serum theophylline levels.
No data; not applicable.
Weight-based: 10-16 mg/kg/day theophylline equivalent divided every 6-8 hours; maximum 400 mg/day. Adjust based on serum levels.
No data; not applicable.
Elderly patients: initial dose of 130 mg orally every 8 hours; titrate gradually; monitor serum theophylline levels due to reduced clearance.
No data; not applicable.
Theophylline has a narrow therapeutic index; serious adverse effects including seizures and arrhythmias can occur at levels close to therapeutic range. Do not exceed recommended doses. Use caution in patients with cardiac or hepatic impairment.
None
Theophylline toxicity is dose-related; monitor serum levels. Caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, or cardiovascular disease. Drug interactions with quinolones, macrolides, and cimetidine can increase theophylline levels.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or guaifenesin, active peptic ulcer disease, seizure disorders (unless controlled), and severe cardiac arrhythmias.
Hypersensitivity to arformoterol or any component of the formulation
Avoid high-fat meals with extended-release formulations as they may alter absorption. Limit caffeine-containing foods/beverages (coffee, tea, chocolate) due to additive CNS stimulation. No significant food interactions with guaifenesin.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no known teratogenicity but may cause fetal tachycardia, jitteriness, or transient neonatal effects (e.g., irritability, vomiting) due to transplacental passage. Guaifenesin: Limited human data; animal studies not indicative of teratogenicity. Overall, Asbron is considered relatively low risk, but non-pharmacologic measures preferred in first trimester.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with an average milk-to-plasma ratio of 0.67. Maximum milk concentration correlates with maternal serum levels. With typical maternal doses, infant serum levels may reach 2-4 mcg/m L, rarely causing irritability or poor feeding. Guaifenesin is likely minimally transferred. Asbron is considered compatible with breastfeeding; observe infant for signs of theophylline side effects (jitteriness, insomnia).
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Theophylline clearance increases by 20-30% in pregnancy due to increased hepatic metabolism and volume of distribution, particularly in second and third trimesters. Starting doses should be based on non-pregnant recommendations, but maintenance doses may need to be increased by up to 30% to achieve therapeutic levels. Monitor serum levels every 1-2 weeks and adjust dose to maintain trough 5-10 mcg/m L (lower end to minimize fetal exposure). Postpartum, clearance decreases rapidly; reduce dose and monitor levels closely to avoid toxicity.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline has a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L) due to variable metabolism. Guaifenesin is an expectorant but evidence for efficacy is limited. Avoid in patients with active peptic ulcer disease or seizure disorders. Cimetidine, fluoroquinolones, and macrolides increase theophylline levels; smoking and rifampin decrease levels.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take Asbron exactly as prescribed; do not crush or chew extended-release tablets.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of theophylline toxicity: nausea, vomiting, insomnia, tremors, fast heartbeat.,Do not stop abruptly; dosage tapering may be needed.,Stay hydrated to help guaifenesin work effectively.,Avoid alcohol as it may increase side effects like dizziness.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASBRON vs AEROLONE, answered by our medical review team.
ASBRON is a Bronchodilator that works by Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASBRON and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASBRON is: 1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASBRON and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASBRON is classified as Category C. Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no . AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.